Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 49: 1434-1436, 2003; 10.1373/49.9.1434
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fahie-Wilson, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fahie-Wilson, M.
Related Collections
Right arrow Laboratory Management
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Cancer Diagnostics (since 2002)
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2003;49:1434-1436.)
© 2003 American Association for Clinical Chemistry, Inc.


Editorials

In Hyperprolactinemia, Testing for Macroprolactin Is Essential

Michael Fahie-Wilson1

1 Department of Clinical Biochemistry, Southend Hospital, Westcliff-on-Sea, Essex SS0 0RY, United Kingdom, Fax 44-1702-221059, E-mail mfahie-wilson@southend.nhs.wk

The first 300 words of the full text of this article appear below.

Autonomous secretion of prolactin (PRL) by a pituitary prolactinoma is a relatively common endocrine disorder characterized by increased serum concentrations of PRL and symptoms of menstrual irregularity, infertility, and galactorrhea in women and impotence and lack of libido in men (1). These clinical symptoms are common, and measurement of serum PRL is a key investigation used to identify the minority of patients who have hyperprolactinemia and warrant further investigation and who may benefit from treatment with dopamine agonists. Unfortunately, the laboratory finding of hyperprolactinemia is not specific because increased serum immunoreactive PRL may be caused by the presence of a high-molecular-mass complex of PRL (macroprolactin), which has been found in asymptomatic patients (2) and therefore appears to lack the biological activity associated with the normal, monomeric 23-kDa form of PRL. This problem is compounded by the limited sensitivity and specificity of pituitary imaging techniques in the confirmation of prolactinoma (1).

The report by Suliman et al. (3) in this issue carries two messages of considerable importance for clinical chemists: (a) hyperprolactinemia attributable to macroprolactin is a frequent cause of misdiagnosis and mismanagement of patients; and (b) this problem could be avoided if laboratories applied a screening test to all samples with increased total serum PRL to detect the presence of macroprolactin and reported a measure of the bioactive, monomeric PRL concentration.

Using gel-filtration chromatography (GFC), Suh and Frantz (4) demonstrated nearly 30 years ago that minor proportions of the total serum immunoreactive PRL circulate as high-molecular-mass forms, which are referred to as big PRL (40–60 kDa) and big-big or macroprolactin (150–170 kDa). Hyperprolactinemia attributable to a predominance of the fraction with the highest molecular mass was observed by Andersen et al. (5) in a patient complaining of infertility . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
L. Beltran, M. N. Fahie-Wilson, T. J. McKenna, L. Kavanagh, and T. P. Smith
Serum Total Prolactin and Monomeric Prolactin Reference Intervals Determined by Precipitation with Polyethylene Glycol: Evaluation and Validation on Common ImmunoAssay Platforms
Clin. Chem., October 1, 2008; 54(10): 1673 - 1681.
[Abstract] [Full Text] [PDF]


Home page
Ann Clin BiochemHome page
S. Ram, B. Harris, J. J R Fernando, R. Gama, and M. Fahie-Wilson
False-positive polyethylene glycol precipitation tests for macroprolactin due to increased serum globulins
Ann Clin Biochem, May 1, 2008; 45(3): 256 - 259.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
L. Kavanagh, T. J. McKenna, M. N. Fahie-Wilson, J. Gibney, and T. P. Smith
Specificity and Clinical Utility of Methods for the Detection of Macroprolactin
Clin. Chem., July 1, 2006; 52(7): 1366 - 1372.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
J. Schiettecatte, A. Van Opdenbosch, E. Anckaert, J. De Schepper, K. Poppe, B. Velkeniers, and J. Smitz
Immunoprecipitation for Rapid Detection of Macroprolactin in the Form of Prolactin-Immunoglobulin Complexes
Clin. Chem., September 1, 2005; 51(9): 1746 - 1748.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Gibney, T. P. Smith, and T. J. McKenna
The Impact on Clinical Practice of Routine Screening for Macroprolactin
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3927 - 3932.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
S. Ram, D. Blumberg, P. Newton, N. R. Anderson, and R. Gama
Raised serum prolactin in rheumatoid arthritis: genuine or laboratory artefact?
Rheumatology, October 1, 2004; 43(10): 1272 - 1274.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
T. C. Friedman, W. T. Couldwell, M. H. Weiss, E. R. Laws Jr., G. L. Hortin, A. Colao, G. Lombardi, and J. Schlechte
Prolactinomas
N. Engl. J. Med., March 4, 2004; 350(10): 1054 - 1057.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.